Ankit A. Desai

Haplotype analysis of UGT1A1 and UGT1A9 gene polymorphisms related to the glucuronidation of SN-38, the active metabolite of irinotecan

M. Ratain, Soma Das, A. Rienzo, 2004 .

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma (RCC)

M. Ratain, K. Flaherty, M. Gore, 2005 .

Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers

L. Cavallari, C. McDonough, M. Arwood, 2021, The Pharmacogenomics Journal.

eNAMPT neutralization reduces preclinical ARDS severity via rectified NFkB and Akt/mTORC2 signaling

L. Cancio, C. Bime, A. Cress, 2022, Scientific Reports.

SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy

Haiyang Tang, S. Black, P. Ran, 2023, Signal Transduction and Targeted Therapy.

Development of a pharmacokinetic (PK) model and assessment of patient (pt) covariate effects on dose-dependent PK following different dosing schedules in two phase I trials of AP23573 (AP), a mTOR inhibitor

M. Ratain, A. Tolcher, M. Mita, 2005 .

A phase II study of imatinib mesylate (IM) and interferon-alpha (IFNA) in metastatic renal cell carcinoma (RCC)

W. Stadler, B. Polite, A. Peterson, 2005 .

A phase I trial of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refractory or advanced malignancies: A pharmacokinetic (PK) and pharmacodynamic (PD) analysis.

M. Ratain, L. Berk, C. Bedrosian, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.

R. Schilsky, M. Ratain, W. Stadler, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.